Public Employees Retirement Association of Colorado Lowers Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Public Employees Retirement Association of Colorado reduced its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 249,326 shares of the company’s stock after selling 6,500 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Teva Pharmaceutical Industries were worth $3,518,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of TEVA. Clal Insurance Enterprises Holdings Ltd grew its position in Teva Pharmaceutical Industries by 7.1% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock worth $342,788,000 after purchasing an additional 2,188,212 shares during the last quarter. Meitav Investment House Ltd. grew its position in Teva Pharmaceutical Industries by 82.8% during the 4th quarter. Meitav Investment House Ltd. now owns 4,305,674 shares of the company’s stock worth $44,914,000 after purchasing an additional 1,950,500 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in Teva Pharmaceutical Industries by 6.9% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock worth $301,920,000 after purchasing an additional 1,860,000 shares during the last quarter. Glenview Capital Management LLC purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth $16,752,000. Finally, Norges Bank purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth $14,376,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Down 0.9 %

Shares of NYSE TEVA opened at $16.52 on Tuesday. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20. Teva Pharmaceutical Industries Limited has a 52 week low of $8.06 and a 52 week high of $17.69. The firm has a 50-day moving average price of $16.76 and a 200 day moving average price of $14.59. The stock has a market capitalization of $18.71 billion, a price-to-earnings ratio of -40.65, a price-to-earnings-growth ratio of 1.50 and a beta of 0.90.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.46 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.03). Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. The company had revenue of $3.82 billion during the quarter, compared to analyst estimates of $3.70 billion. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on TEVA shares. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, June 5th. UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $20.00 target price (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. Bank of America lifted their target price on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 25th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $18.56.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Roberto Mignone sold 519,000 shares of the business’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the completion of the transaction, the director now owns 981,000 shares of the company’s stock, valued at approximately $16,706,430. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Vikki L. Conway sold 15,219 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. Over the last quarter, insiders sold 549,719 shares of company stock worth $9,353,736. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.